Meeting
2014 ASCO Annual Meeting
Phase 2 trial of trastuzumab and/or everolimus in hormone-resistant, HER2-negative metastatic breast cancer.
Authors
Amelia Bruce Zelnak
The Winship Cancer Institute of Emory University, Atlanta, GA
Amelia Bruce Zelnak , Elisavet Paplomata , Sujatha Murali , Geetha D. Vallabhaneni , Virginia G. Kaklamani , Xiaoxian Li , Yuan Liu , Ruth O'Regan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT00912340
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 576^)
DOI
10.1200/jco.2014.32.15_suppl.576
Abstract #
576^
Poster Bd #
40
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).
First Author: Erica Michelle Stringer-Reasor
Poster
2012 ASCO Annual Meeting
Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).
First Author: Mothaffar F. Rimawi
First Author: Nicholas Patrick McAndrew
Poster
2022 ASCO Annual Meeting
Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.
First Author: Komal L. Jhaveri